» Articles » PMID: 28491223

[Neuroendocrine Carcinoma of the Bladder: About 5 Cases]

Overview
Journal Pan Afr Med J
Date 2017 May 12
PMID 28491223
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Neuroendocrine carcinoma of the bladder is a rare histological entity, characterized by the ability to metastasize quickly and associated with a poor prognosis. The purpose of this study was to analyze the clinical, histological, therapeutic and prognostic characteristics of neuroendocrine carcinoma of the bladder. We conducted a retrospective study collecting data from the medical records of 5 patients in the Department of Urology, at the Ibn Sina University Hospital during the period between January 2008 and June 2015. The average age was 63 years. Four males and one female were involved in the sudy. The neuroendocrine carcinoma was pure in four cases and impure or associated with urothelial component in one case. In two patients metastases were present at initial diagnosis. In one case, cystectomy was performed followed by neoadjuvant chemotherapy; chemoradiotherapy was performed in two cases and palliative chemotherapy in the other two cases. The median survival was 10 months. Only one patient was alive, with a follow-up period of 20 months. The management of neuroendocrine carcinoma of the bladder is not standardized, several therapeutic options have been proposed: surgery, radiation therapy and chemotherapy.

Citing Articles

Neuroendocrine Carcinoma of the Bladder: A Case Report.

Gao P, Li X, He Z, Xu Y, Zhang Z Res Rep Urol. 2024; 16:137-142.

PMID: 38894710 PMC: 11184159. DOI: 10.2147/RRU.S470653.


Neuroendocrine Carcinoma of the Urinary Bladder: CT Findings and Radiomics Signature.

Coppola A, Gatta T, Pini G, Scordi G, Fontana F, Piacentino F J Clin Med. 2023; 12(20).

PMID: 37892647 PMC: 10607129. DOI: 10.3390/jcm12206510.

References
1.
Siefker-Radtke A, Kamat A, Grossman H, Williams D, Qiao W, Thall P . Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol. 2009; 27(16):2592-7. PMC: 4879720. DOI: 10.1200/JCO.2008.19.0256. View

2.
Bex A, Nieuwenhuijzen J, Kerst M, Pos F, van Boven H, Meinhardt W . Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer. Urology. 2005; 65(2):295-9. DOI: 10.1016/j.urology.2004.09.049. View

3.
Chekrine T, De Bari B, Cassier P, Kulisa M, Chapet O, Mornex F . [Small cell neuroendocrine carcinoma of the bladder: A case report and review of the literature]. Cancer Radiother. 2011; 15(3):250-3. DOI: 10.1016/j.canrad.2010.11.013. View

4.
Vincendeau S, de Lajarte-Thirouard A, Bensalah K, Guille F, Lobel B, Patard J . [Neuroendocrine differentiation of bladder tumors]. Prog Urol. 2003; 13(3):375-84. View

5.
Ismaili N, Heudel P, Elkarak F, Kaikani W, Bajard A, Ismaili M . Outcome of recurrent and metastatic small cell carcinoma of the bladder. BMC Urol. 2009; 9:4. PMC: 2700133. DOI: 10.1186/1471-2490-9-4. View